Persistence of Detectable Anti-Pneumococcal Antibodies 4 Years After Pneumococcal Polysaccharide Vaccination in a Randomised Controlled Trial: The Australian Study for the Prevention through Immunisation of Cardiovascular Events (AUSPICE).

Attia, J; Horvat, JC; Hunter, T; Hansbro, PM; Hure, A; Peel, R; Ren, S; Dizon, J; Chiu, S; Srikusalanukul, W; Greenough, R; Abhayaratna, WP; AUSPICE Investigators,

Persistence of Detectable Anti-Pneumococcal Antibodies 4 Years After Pneumococcal Polysaccharide Vaccination in a Randomised Controlled Trial: The Australian Study for the Prevention through Immunisation of Cardiovascular Events (AUSPICE).

Attia, J Horvat, JC Hunter, T Hansbro, PM Hure, A Peel, R Ren, S Dizon, J Chiu, S Srikusalanukul, W Greenough, R Abhayaratna, WP AUSPICE Investigators,

Permalink

Publisher:: ELSEVIER SCIENCE INC
Publication Type:: Journal Article
Citation:: Heart Lung Circ, 2023, 32, (11), pp. 1378-1385
Issue Date:: 2023-11

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (392.42 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Attia, J
dc.contributor.author	Horvat, JC
dc.contributor.author	Hunter, T
dc.contributor.author	Hansbro, PM
dc.contributor.author	Hure, A
dc.contributor.author	Peel, R
dc.contributor.author	Ren, S
dc.contributor.author	Dizon, J
dc.contributor.author	Chiu, S
dc.contributor.author	Srikusalanukul, W
dc.contributor.author	Greenough, R
dc.contributor.author	Abhayaratna, WP
dc.contributor.author	AUSPICE Investigators,
dc.date.accessioned	2024-01-25T05:37:06Z
dc.date.available	2023-09-02
dc.date.available	2024-01-25T05:37:06Z
dc.date.issued	2023-11
dc.identifier.citation	Heart Lung Circ, 2023, 32, (11), pp. 1378-1385
dc.identifier.issn	1443-9506
dc.identifier.issn	1444-2892
dc.identifier.uri	http://hdl.handle.net/10453/174950
dc.description.abstract	AIM: Mouse models have indicated that the pneumococcal polysaccharide vaccine (PPV) can reduce atherosclerosis. This is probably through a process of molecular mimicry, where phosphorylcholine in the capsular polysaccharide of the vaccine elicits antibodies that cross-react with oxidised low-density lipoprotein and reduce plaque. We investigated whether a similar mechanism occurs in humans. METHODS: A large national blinded, randomised, placebo-controlled trial of the PPV (Australian Study for the Prevention through Immunisation of Cardiovascular Events [AUSPICE]) is underway with fatal and nonfatal cardiovascular disease (CVD) events as the primary outcome. Participants at one centre agreed to a substudy measuring a number of biomarkers and surrogates of CVD over 4 years, including anti-pneumococcal antibodies (immunoglobulin G and immunoglobulin M), C-reactive protein, carotid intima-media thickness, pulse wave velocity, insulin, fasting blood glucose, glycated haemoglobin, and hepatorenal index. RESULTS: Antipneumococcal immunoglobulin G and immunoglobulin M were both present and statistically significantly increased in the treated group compared to control at 4 years. However, there were no differences in any of the surrogate measures of CVD or metabolic markers at 4 years. CONCLUSIONS: While there were prolonged differences in anti-pneumococcal antibody titres following PPV vaccination, these did not appear to provide any cardioprotective effect, as measured by a range of markers. Final results using the fatal and nonfatal CVD events await the completion of national health record linkage next year. TRIAL REGISTRATION: ACTRN12615000536561.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	ELSEVIER SCIENCE INC
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1079187
dc.relation	http://purl.org/au-research/grants/nhmrc/1175134
dc.relation	http://purl.org/au-research/grants/nhmrc/1079187
dc.relation.ispartof	Heart Lung Circ
dc.relation.isbasedon	10.1016/j.hlc.2023.09.006
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology, 1117 Public Health and Health Services
dc.subject.classification	Cardiovascular System & Hematology
dc.subject.classification	3201 Cardiovascular medicine and haematology
dc.subject.classification	4203 Health services and systems
dc.subject.classification	4206 Public health
dc.subject.mesh	Animals
dc.subject.mesh	Mice
dc.subject.mesh	Humans
dc.subject.mesh	Carotid Intima-Media Thickness
dc.subject.mesh	Pulse Wave Analysis
dc.subject.mesh	Australia
dc.subject.mesh	Streptococcus pneumoniae
dc.subject.mesh	Vaccination
dc.subject.mesh	Pneumococcal Vaccines
dc.subject.mesh	Immunoglobulin G
dc.subject.mesh	Immunoglobulin M
dc.subject.mesh	Cardiovascular Diseases
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Mice
dc.subject.mesh	Streptococcus pneumoniae
dc.subject.mesh	Cardiovascular Diseases
dc.subject.mesh	Immunoglobulin G
dc.subject.mesh	Immunoglobulin M
dc.subject.mesh	Pneumococcal Vaccines
dc.subject.mesh	Vaccination
dc.subject.mesh	Australia
dc.subject.mesh	Carotid Intima-Media Thickness
dc.subject.mesh	Pulse Wave Analysis
dc.title	Persistence of Detectable Anti-Pneumococcal Antibodies 4 Years After Pneumococcal Polysaccharide Vaccination in a Randomised Controlled Trial: The Australian Study for the Prevention through Immunisation of Cardiovascular Events (AUSPICE).
dc.type	Journal Article
utslib.citation.volume	32
utslib.location.activity	Australia
utslib.for	1102 Cardiorespiratory Medicine and Haematology
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	University of Technology Sydney/Strength - CFI - Centre for Inflammation
utslib.copyright.status	open_access	*
dc.date.updated	2024-01-25T05:37:04Z
pubs.issue	11
pubs.publication-status	Published
pubs.volume	32
utslib.citation.issue	11

Abstract:

AIM: Mouse models have indicated that the pneumococcal polysaccharide vaccine (PPV) can reduce atherosclerosis. This is probably through a process of molecular mimicry, where phosphorylcholine in the capsular polysaccharide of the vaccine elicits antibodies that cross-react with oxidised low-density lipoprotein and reduce plaque. We investigated whether a similar mechanism occurs in humans. METHODS: A large national blinded, randomised, placebo-controlled trial of the PPV (Australian Study for the Prevention through Immunisation of Cardiovascular Events [AUSPICE]) is underway with fatal and nonfatal cardiovascular disease (CVD) events as the primary outcome. Participants at one centre agreed to a substudy measuring a number of biomarkers and surrogates of CVD over 4 years, including anti-pneumococcal antibodies (immunoglobulin G and immunoglobulin M), C-reactive protein, carotid intima-media thickness, pulse wave velocity, insulin, fasting blood glucose, glycated haemoglobin, and hepatorenal index. RESULTS: Antipneumococcal immunoglobulin G and immunoglobulin M were both present and statistically significantly increased in the treated group compared to control at 4 years. However, there were no differences in any of the surrogate measures of CVD or metabolic markers at 4 years. CONCLUSIONS: While there were prolonged differences in anti-pneumococcal antibody titres following PPV vaccination, these did not appear to provide any cardioprotective effect, as measured by a range of markers. Final results using the fatal and nonfatal CVD events await the completion of national health record linkage next year. TRIAL REGISTRATION: ACTRN12615000536561.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/174950